Loading
NRI·Psychiatry - Antidepressants
Major Depressive Disorder
Max Dose
12 mg/day
Half-life
13 h
Activation
HIGH
Sweating
SEVERE
Overview
Highly selective Noradrenaline Reuptake Inhibitor (NRI). Has absolutely zero effect on serotonin. Acts as an activating, 'wake-up' antidepressant for patients with severe fatigue and psychomotor retardation.
Maximum Dose
Max 12 mg/day (Usually 4 mg BD).
Clinical Focus
The massive noradrenaline boost acts like synthetic adrenaline on the body. High risk of tachycardia, sweating, and urinary retention.
Bottom Line
Reboxetine is a selective noradrenaline reuptake inhibitor for depression, but has questionable efficacy compared to SSRIs and causes urinary retention, insomnia, and dry mouth.
Brand Names
Edronax
Oral Routes
Tablets (4 mg). Usually scored to halve.
Prescribing & PBS
Authority Required (PBS).
Primary
Major Depressive Disorder.
Off-Label
ADHD (as an alternative to Atomoxetine/Stimulants).
Clinical Place
Niche drug. Used as an adjunct to SSRIs to provide energy and focus, or as monotherapy for patients who cannot tolerate serotonergic side effects (sexual dysfunction, weight gain).